Related Experiment Video
Updated: Jul 23, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.3K
Arterial Hypertension-clinical trials update 2023
Felix Götzinger1, Michael Kunz2, Lucas Lauder2
1From the Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, 66424, Homburg, Germany. felix.goetzinger@uks.eu.
Summary
This review highlights key 2022-2023 hypertension trial findings, including new treatments for resistant hypertension and optimal medication timing. It addresses blood pressure targets and novel device-based therapies for better cardiovascular outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Arterial hypertension significantly increases cardiovascular morbidity and mortality.
- Hypertension research is a dynamic and evolving field.
- Effective management strategies are crucial for patient outcomes.
Purpose of the Study:
- To summarize pivotal clinical trials in hypertension research from 2022 and early 2023.
- To present new findings on pharmacological and device-based treatments.
- To discuss optimal blood pressure targets and treatment inertia.
Main Methods:
- Review of major clinical trials published in 2022 and early 2023.
- Analysis of data on pharmacological interventions, including resistant hypertension.
- Inclusion of studies on pregnancy-related hypertension and post-stroke blood pressure management.
Main Results:
- New pharmacological approaches for resistant hypertension show promise.
- Optimal timing for antihypertensive medication intake is further elucidated.
- Novel device-based therapies are emerging as treatment options.
- Guideline inertia remains a challenge in blood pressure management.
Conclusions:
- Recent trials offer significant advancements in hypertension management.
- Optimizing treatment targets and addressing inertia are critical.
- Emerging therapies, including device-based interventions, expand treatment possibilities.
Related Concept Videos
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
27
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
27
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
17
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
17
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
01:29Hypertension II: Pathophysiology
20
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
20
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
01:26Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13